Only a diversified portfolio of vaccines can reduce technology and supply risks, the developers stressed
MOSCOW, January 24. /TASS/. Developers of Russia’s Sputnik V anti-coronavirus vaccine said on Sunday they will continue to work with the European Union and AstraZeneca, a British-Sweden pharmaceutical company, to ensure access to the Russian vaccine and its components across the globe.
"Only a diversified portfolio of vaccines can reduce technology and supply risks. SputnikV, already approved by 12 nations, will continue its work with EU and AstraZeneca to enable access to the Sputnik V vaccine and its components worldwide," as follows from a message posted on the Sputnik V official Twitter account.